rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RNA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Astrosalva Therapeutics Adds Michael MacLean, Former CFO of Novartis-Acquired Avidity Biosciences, to Strategic Advisory Board
      Nov 12MorningstarRNANVS
      Pharma sector doubles down on AI to slash costs, timelines
      Sep 16ReutersRNAPFE
      Novartis Sees Avidity Drug Fail in Third Setback in a Week
      Sep 8BloombergRNANVS
      Novartis Stock Drops After Another Trial Setback

      The failure of a neuromuscular treatment is a blow to the drugmaker’s efforts to revive its growth prospects.

      Sep 8WSJRNANVS
      Novartis’ $12bn Avidity bet falters on late-stage del-desiran flop
      Sep 8Yahoo FinanceRNANVS

      This is the newest page. Registered accounts read further back.